Sant Pau - Institut de Recerca

Main lines of research

Research is partially conducted on the premises of the Translational Research Laboratory of the Catalan Oncology Institute (ICO)-Bellvitge Biomedical Research Institute (IDIBELL) under a framework agreement between Sant Pau and the ICO.

Modulation of Radiosensitivity

Modulation of radiosensitivity by SRC protein inhibitors in combination with anti-EGFR.
Modulation of radiosensitivity by HMG-CoA reductase inhibitors in combination with anti-EGFR.

SBRT for Patients with Lung Cancer and with Oligometastases

Stereotactic body radiotherapy techniques in radical treatment of patients with early-stage non-surgical lung cancer and selected patients with non-surgical oligometastases.

Radiation Therapy Based on PET/CT Functional Imaging of Tumours

Implementation of planning techniques for radiotherapy treatment with PET/CT for chest locations and head and neck tumours squamous cell tumours.
Image-guided radiotherapy and respiratory movement control.
Salvage brachytherapy for local recurrence after external beam radiotherapy in prostate cancer.
Hypofractionated intensity-modulated GRT in prostate cancer.

Challenges

Establish relatively radioresistant cell lines compared with the parental cells from which they derive (by clonal selection).
Determine the resistant phenotype in cultures and xenografts.
Determine molecular radioresistance.
Evaluate the effect on carcinomas of SRC and HMG-CoA reductase inhibitors in combination with anti-EGFR.
Explore signal transduction changes in the EGFR-MAPK pathway and SRC-EGFR/SRCSTAT3 cooperation induced by SRC and HMG-CoA reductase inhibitors.

Group coordination

SANCHO PARDO, GEMMA FGS
gsancho@santpau.cat

Members

Balart Serra, Josep FGS
Cifuentes Antolinez, Patricia IR
Farre Bernado, Nuria FGS
Isern Verdum, Josep FGS
Julia Sanahuja, Joan Carles FGS
Majercakova , Katarina FGS
Mera Errasti, Maria Arantzazu FGS
Montezuma Niño, Laura Constanza FGS
Rojas Cordero, Jady Vivian FGS
Soto Cambres, Ana Maria FGS
Vila Capel, Antoni FGS

Publications 2023

(JIF 2023)

-Bonet M, Gonzalez D, Baquedano JE, Garcia E, Altabas M, Casas F, Feltes N, Ferrer F, Foro P, Fuentes R, Galdeano M, Gomez D, Henriquez I, Jove J, Lozano J, Maldonado X, Mases J, Membrive I, Paredes S, Rosello A, Sancho G, Mira M. Management of high-risk and post-operative non-metastatic prostate cancer in Catalonia: an expert Delphi consensus. Clinical & Translational Oncology. 2023; 25(4). DOI:10.1007/s12094-022-03005-4. PMID:36436177. IF:2,800 (Q2/5D). Document type: Article.

-León X, Farré N, Montezuma L, Holgado A, Vásquez R, Neumann E, Quer M. Results of radiotherapy in oropharyngeal carcinomas. Acta Otorrinolaringologica Espanola. 2023; 74(3). DOI:10.1016/j.otorri.2022.04.002. PMID:37149134. IF:0,900 (Q3/8D). Document type: Article.

-Lococo F, Boldrini L, Diepriye CD, Evangelista J, Nero C, Flamini S, Minucci A, De Paolis E, Vita E, Cesario A, Annunziata S, Calcagni ML, Chiappetta M, Cancellieri A, Larici AR, Cicchetti G, Troost E, Róza Á, Farré N, Ozturk E, Van D, Leoncini F, Urbani A, Trisolini R, Bria E, Giordano A, Rindi G, Sala E, Tortora G, Valentini V, Boccia S, Margaritora S, Scambia G. Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study. BMC CANCER. 2023; 23(1):540. DOI:10.1186/s12885-023-10997-x. PMID:37312079. IF:3,400 (Q2/4D). Document type: Article.

-Moreno P, Gamboa O, Gonzalez C, Romero A, Serra JB, Diaz GD, Malaver G, Bouleftour W, Magne N. hTERT and IGF-1R Proteins Expression in Response to Treatment in Patients with HPV Alpha 9-Positive Cervical Cancer. RADIATION RESEARCH. 2023; 199(5). DOI:10.1667/RADE-22-00121.1. PMID:36888727. IF:2,500 (Q2/4D). Document type: Article.

-Oladeru OT, Dunn SA, Li J, Coles CE, Yamauchi C, Chang JS, Cheng SHC, Kaidar O, Meattini I, Ramiah D, Kirby A, Hijal T, Marta GN, Poortmans P, Isern J, Zissiadis Y, Offersen BV, Refaat T, Elsayad K, Hijazi H, Dengina N, Belkacemi Y, Luo FD, Lu S, Griffin C, Collins M, Ryan P, Larios D, Warren LE, Punglia RS, Wong JS, Spiegel DY, Jagsi R, Taghian A, Bellon JR, Ho AY. Looking Back: International Practice Patterns in Breast Radiation Oncology From a Case-Based Survey Across 54 Countries During the First Surge of the COVID-19 Pandemic. Jco Global Oncology. 2023; 9:e2300010. DOI:10.1200/GO.23.00010. PMID:37471670. IF:3,200 (Q2/5D). Document type: Article.

-Pérez-Fidalgo JA, Ortega E, Ponce J, Redondo A, Sevilla I, Valverde C, Isern Verdum J, de Alava E, Galera López M, Marquina G, Sebio A. Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS). Ther Adv Med Oncol. 2023; 15:17588359231157645. DOI: 10.1177/17588359231157645. PMID: 37007636. IF:4,300 (Q2/3D). Document type: Review.

-Redondo S, Garcia I, Vila A, Esquirol A, Portos JM, Novelli S, Saavedra S, Moreno C, Garrido A, Arguello M, Onate G, Lopez J, Caballero AC, Miqueleiz S, Briones J, Sierra J, Sancho G, Martino R. Sequence matters: Total body irradiation (TBI)-based myeloablative conditioning with post-transplant cyclophosphamide may reduce the early nonrelapse mortality compared with pretransplant cyclophosphamide plus TBI. EUROPEAN JOURNAL OF HAEMATOLOGY. 2023; 111(1). DOI:10.1111/ejh.13978. PMID:37058419. IF:2,300 (Q2/5D). Document type: Article.

Publications 2022

(JIF 2022)

Camacho M, Leon X, Pujol A, Montezuma L, Quer M, Garcia J. Prognostic value of transcriptional expression of fibronectin type III domain-containing 4 (FNDC4) in head and neck carcinoma patients treated with chemoradiotherapy. Clinical & Translational Oncology. 2022; 24(11). DOI:10.1007/s12094-022-02870-3. PMID:35752749. IF:3,4 (Q3/6D). Document type: Article.
Eraso A, Sanz J, Molla M, Reyes V, Pedro A, Arenas M, Martinez E, Ballester R, Cambra MJ, Garcia V, Prades JL, Borras JM, Algara M. Evidence-based guidelines for hypofractionated radiation in breast cancer: conclusions of the Catalan expert working group. Clinical & Translational Oncology. 2022; 24(8). DOI:10.1007/s12094-022-02798-8. PMID:35190961. IF:3,4 (Q3/6D). Document type: Article.
Lara PC, Rodriguez JI, Palacios A, Lozano A, Hervas A, Villafranca E, Gomez A, Sancho G, Maldonado X. Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer. Frontiers in Oncology. 2022; 12:891886. DOI:10.3389/fonc.2022.891886. PMID:35912190. IF:4,7 (Q2/4D). Document type: Article.
Manrique A, Salazar J, Arranz MJ, Bague S, Orellana R, Lopez A, Cerda P, Gracia I, Majercakova K, Peiro A, Trullols L, Fernandez M, Valverde S, Quintana MJ, Bell O, Artigas A, Sebio A. Pharmacogenetic Profiling in High-Risk Soft Tissue Sarcomas Treated with Neoadjuvant Chemotherapy. Journal of Personalized Medicine. 2022; 12(4):618. DOI:10.3390/jpm12040618. PMID:35455734. Document type: Article.
Rodríguez F, Caruana P, De la Fuente N, Español P, Gámez M, Balart J, Llurba E, RAMON N, Ruiz R, Martín C, Corchero JL, Céspedes MV. Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges. Biomolecules. 2022; 12(6):784. DOI:10.3390/biom12060784. PMID:35740909. IF:5,5 (Q1/3D). Document type: Review.
Suarez JF, Zamora V, Garin O, Gutierrez C, Pont A, Pardo Y, Goni A, Marino A, Hervas A, Herruzo I, Cabrera P, Sancho G, de Leon JP, Macias V, Guedea F, Vigues F, Castells M, Ferrer M, Multictr Spanish Clinically Lo GRP. Mortality and biochemical recurrence after surgery, brachytherapy, or external radiotherapy for localized prostate cancer: a 10-year follow-up cohort study. Scientific Reports. 2022; 12(1):12589. DOI:10.1038/s41598-022-16395-w. PMID:35869124. IF:4,6 (Q2/3D). Document type: Article.

Publications 2021

Amador M, Matias X, Sancho G, Martinez JC, de la Torre JC, Saiz AP, Garrido P, Garcia R, Rodriguez A, Paz L. Impact of the COVID-19 pandemic on the care of cancer patients in Spain. ESMO Open. 2021; 6(3):100157. DOI:10.1016/j.esmoop.2021.100157. PMID:34015642. IF:6,883.
Campos FL, Pardo GS, Pijoan XM, Zilli T, Lorenzo FC, Moron AH. Is hypofractionation acceptable for prostate bed radiotherapy?. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 2021; 39(6). DOI:10.1016/j.urolonc.2021.02.002. PMID:34049781. IF:2,954.
de Dios NR, Counago F, Murcia M, Rico M, Calvo P, Samper P, Vallejo C, Luna J, Trueba I, Sotoca A, Cigarral C, Farre N, Manero RM, Duran X, Gispert JD, Sanchez G, Rognoni T, Torrente M, Capellades J, Jimenez M, Cabada T, Blanco M, Alonso A, Martinez J, Escribano J, Gonzalez B, Lopez JL. Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECP-SEOR Study. JOURNAL OF CLINICAL ONCOLOGY. 2021; 39(28). DOI:10.1200/JCO.21.00639. PMID:34379442. IF:50,717.
Garin O, Suarez JF, Guedea F, Pont A, Pardo Y, Goni A, Marino A, Hervas A, Herruzo I, Cabrera P, Sancho G, de Leon JP, Macias V, Gutierrez C, Castells M, Ferrer M. Comparative Effectiveness Research in Localized Prostate Cancer: A 10-Year Follow-up Cohort Study. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2021; 110(3). DOI:10.1016/j.ijrobp.2020.12.032. PMID:33388360. IF:8,013.
Lozano A, Marruecos J, Rubio J, Farre N, Gomez J, Morera R, Planas I, Lanzuela M, Vazquez MG, Cascallar L, Giralt J, Escames G, Valenti V, Grima P, Bosser R, Tarrago C, Mesia R. Randomized placebo-controlled phase II trial of high-dose melatonin mucoadhesive oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing radiation therapy concurrent with systemic treatment. Clinical & Translational Oncology. 2021; 23(9). DOI:10.1007/s12094-021-02586-w. PMID:33738704. IF:3,340.
Mahantshetty U, Banerjee S, Sturdza A, Kirisits C, Majercakova K, Schmid MP, Hande V, Potter R. Quantitative and qualitative application of clinical drawings for image-guided brachytherapy in cervical cancer patients. Journal of Contemporary Brachytherapy. 2021; 13(5). DOI:10.5114/jcb.2021.110273. PMID:34759975. IF:1,788.
Marta GN, Ramiah D, Kaidar O, Kirby A, Coles C, Jagsi R, Hijal T, Sancho G, Zissiadis Y, Pignol JP, Ho AY, Cheng SHC, Offersen BV, Meattini I, Poortmans P. The Financial Impact on Reimbursement of Moderately Hypofractionated Postoperative Radiation Therapy for Breast Cancer: An International Consortium Report. CLINICAL ONCOLOGY. 2021; 33(5). DOI:10.1016/j.clon.2020.12.008. PMID:33358283. IF:4,925.
Martinez E, Garin O, Pardo Y, Fernandez P, Guix B, Gutierrez C, Boladeras A, Ferrer F, Hernandez T, Ayala A, Egiguren M, Fernandez G, Munoz V, Macias V, Pera J, Pont A, Ferrer M, Guedea F, Sancho G, Palou J, Multicentric Spanish Clinicall GRP. Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost: a prospective multicenter study. Journal of Contemporary Brachytherapy. 2021; 13(1). DOI:10.5114/jcb.2021.103580. PMID:34025730. IF:1,788.
Pötter R, Tanderup K, Schmid MP, Jürgenliemk-Schulz I, Haie-Meder C, Fokdal LU, Sturdza AE, Hoskin P, Mahantshetty U, Segedin B, Bruheim K, Huang F, Rai B, Cooper R, van der Steen-Banasik E, Van Limbergen E, Pieters BR, Tan LT, Nout RA, De Leeuw AAC, et al. [Majercakova K]. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncology. 2021;22(4):538-547. DOI: 1016/S1470-2045(20)30753-1. PMID: 33794207. IF:54,433.
Provencio M, Majem M, Guirado M, Massuti B, de Las Penas R, Ortega AL, Domine M, Marse R, Sala MA, Paredes A, Moran T, Vazquez S, Coves J, Larriba JLG, Sanchez JM, Vicente D, Farre N, Fornos LF, Zapata I, Franco F, Serna R, Romero A, Isla D. Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection. LUNG CANCER. 2021; 153. DOI:10.1016/j.lungcan.2021.01.005. PMID:33453470. IF:6,081.
Sanguedolce F, Pardo GS, Sanchez AM, Lucena JB, Pisano F, Cortez JC, Territo A, Perez JH, Sopena JG, Lopez CE, Breda A, Redorta JP. Radiation-induced haemorrhagic cystitis after prostate cancer radiotherapy: factors associated to hospitalization and treatment strategies. Prostate International. 2021; 9(1). DOI:10.1016/j.prnil.2020.07.006. PMID:33912514. IF:3,070.
Seppenwoolde Y, Majercakova K, Buschmann M, Dorr E, Sturdza AE, Schmid MP, Potter R, Georg D. Early morbidity and dose-volume effects in definitive radiochemotherapy for locally advanced cervical cancer: a prospective cohort study covering modern treatment techniques. STRAHLENTHERAPIE UND ONKOLOGIE. 2021; 197(6). DOI:10.1007/s00066-021-01781-6. PMID:33929558. IF:4,033.
Zhao M, Sanz J, Rodríguez N, Foro P, Reig A, Membrive I, Li X, Huang Y, Montezuma L, Martínez A, Manuel A. Weekly radiotherapy in elderly breast cancer patients: a comparison between two hypofractionation schedules. Clinical & Translational Oncology. 2021;23(2):372-377. DOI:10.1007/s12094-020-02430-7. PMID: 32617869. IF:3,340.

Introduction

Main lines of research

Modulation of Radiosensitivity

Modulation of radiosensitivity by SRC protein inhibitors in combination with anti-EGFR.
Modulation of radiosensitivity by HMG-CoA reductase inhibitors in combination with anti-EGFR.

SBRT for Patients with Lung Cancer and with Oligometastases

Stereotactic body radiotherapy techniques in radical treatment of patients with early-stage non-surgical lung cancer and selected patients with non-surgical oligometastases.

Radiation Therapy Based on PET/CT Functional Imaging of Tumours

Implementation of planning techniques for radiotherapy treatment with PET/CT for chest locations and head and neck tumours squamous cell tumours.
Image-guided radiotherapy and respiratory movement control.
Salvage brachytherapy for local recurrence after external beam radiotherapy in prostate cancer.
Hypofractionated intensity-modulated GRT in prostate cancer.

Challenges

Establish relatively radioresistant cell lines compared with the parental cells from which they derive (by clonal selection).
Determine the resistant phenotype in cultures and xenografts.
Determine molecular radioresistance.
Evaluate the effect on carcinomas of SRC and HMG-CoA reductase inhibitors in combination with anti-EGFR.
Explore signal transduction changes in the EGFR-MAPK pathway and SRC-EGFR/SRCSTAT3 cooperation induced by SRC and HMG-CoA reductase inhibitors.

Team

Group coordination

SANCHO PARDO, GEMMA FGS
gsancho@santpau.cat

Members

Scientific output

Publications 2023

(JIF 2023)

Publications 2022

(JIF 2022)

Camacho M, Leon X, Pujol A, Montezuma L, Quer M, Garcia J. Prognostic value of transcriptional expression of fibronectin type III domain-containing 4 (FNDC4) in head and neck carcinoma patients treated with chemoradiotherapy. Clinical & Translational Oncology. 2022; 24(11). DOI:10.1007/s12094-022-02870-3. PMID:35752749. IF:3,4 (Q3/6D). Document type: Article.
Eraso A, Sanz J, Molla M, Reyes V, Pedro A, Arenas M, Martinez E, Ballester R, Cambra MJ, Garcia V, Prades JL, Borras JM, Algara M. Evidence-based guidelines for hypofractionated radiation in breast cancer: conclusions of the Catalan expert working group. Clinical & Translational Oncology. 2022; 24(8). DOI:10.1007/s12094-022-02798-8. PMID:35190961. IF:3,4 (Q3/6D). Document type: Article.
Lara PC, Rodriguez JI, Palacios A, Lozano A, Hervas A, Villafranca E, Gomez A, Sancho G, Maldonado X. Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer. Frontiers in Oncology. 2022; 12:891886. DOI:10.3389/fonc.2022.891886. PMID:35912190. IF:4,7 (Q2/4D). Document type: Article.
Manrique A, Salazar J, Arranz MJ, Bague S, Orellana R, Lopez A, Cerda P, Gracia I, Majercakova K, Peiro A, Trullols L, Fernandez M, Valverde S, Quintana MJ, Bell O, Artigas A, Sebio A. Pharmacogenetic Profiling in High-Risk Soft Tissue Sarcomas Treated with Neoadjuvant Chemotherapy. Journal of Personalized Medicine. 2022; 12(4):618. DOI:10.3390/jpm12040618. PMID:35455734. Document type: Article.
Rodríguez F, Caruana P, De la Fuente N, Español P, Gámez M, Balart J, Llurba E, RAMON N, Ruiz R, Martín C, Corchero JL, Céspedes MV. Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges. Biomolecules. 2022; 12(6):784. DOI:10.3390/biom12060784. PMID:35740909. IF:5,5 (Q1/3D). Document type: Review.
Suarez JF, Zamora V, Garin O, Gutierrez C, Pont A, Pardo Y, Goni A, Marino A, Hervas A, Herruzo I, Cabrera P, Sancho G, de Leon JP, Macias V, Guedea F, Vigues F, Castells M, Ferrer M, Multictr Spanish Clinically Lo GRP. Mortality and biochemical recurrence after surgery, brachytherapy, or external radiotherapy for localized prostate cancer: a 10-year follow-up cohort study. Scientific Reports. 2022; 12(1):12589. DOI:10.1038/s41598-022-16395-w. PMID:35869124. IF:4,6 (Q2/3D). Document type: Article.

Publications 2021

Amador M, Matias X, Sancho G, Martinez JC, de la Torre JC, Saiz AP, Garrido P, Garcia R, Rodriguez A, Paz L. Impact of the COVID-19 pandemic on the care of cancer patients in Spain. ESMO Open. 2021; 6(3):100157. DOI:10.1016/j.esmoop.2021.100157. PMID:34015642. IF:6,883.
Campos FL, Pardo GS, Pijoan XM, Zilli T, Lorenzo FC, Moron AH. Is hypofractionation acceptable for prostate bed radiotherapy?. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 2021; 39(6). DOI:10.1016/j.urolonc.2021.02.002. PMID:34049781. IF:2,954.
de Dios NR, Counago F, Murcia M, Rico M, Calvo P, Samper P, Vallejo C, Luna J, Trueba I, Sotoca A, Cigarral C, Farre N, Manero RM, Duran X, Gispert JD, Sanchez G, Rognoni T, Torrente M, Capellades J, Jimenez M, Cabada T, Blanco M, Alonso A, Martinez J, Escribano J, Gonzalez B, Lopez JL. Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECP-SEOR Study. JOURNAL OF CLINICAL ONCOLOGY. 2021; 39(28). DOI:10.1200/JCO.21.00639. PMID:34379442. IF:50,717.
Garin O, Suarez JF, Guedea F, Pont A, Pardo Y, Goni A, Marino A, Hervas A, Herruzo I, Cabrera P, Sancho G, de Leon JP, Macias V, Gutierrez C, Castells M, Ferrer M. Comparative Effectiveness Research in Localized Prostate Cancer: A 10-Year Follow-up Cohort Study. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2021; 110(3). DOI:10.1016/j.ijrobp.2020.12.032. PMID:33388360. IF:8,013.
Lozano A, Marruecos J, Rubio J, Farre N, Gomez J, Morera R, Planas I, Lanzuela M, Vazquez MG, Cascallar L, Giralt J, Escames G, Valenti V, Grima P, Bosser R, Tarrago C, Mesia R. Randomized placebo-controlled phase II trial of high-dose melatonin mucoadhesive oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing radiation therapy concurrent with systemic treatment. Clinical & Translational Oncology. 2021; 23(9). DOI:10.1007/s12094-021-02586-w. PMID:33738704. IF:3,340.
Mahantshetty U, Banerjee S, Sturdza A, Kirisits C, Majercakova K, Schmid MP, Hande V, Potter R. Quantitative and qualitative application of clinical drawings for image-guided brachytherapy in cervical cancer patients. Journal of Contemporary Brachytherapy. 2021; 13(5). DOI:10.5114/jcb.2021.110273. PMID:34759975. IF:1,788.
Marta GN, Ramiah D, Kaidar O, Kirby A, Coles C, Jagsi R, Hijal T, Sancho G, Zissiadis Y, Pignol JP, Ho AY, Cheng SHC, Offersen BV, Meattini I, Poortmans P. The Financial Impact on Reimbursement of Moderately Hypofractionated Postoperative Radiation Therapy for Breast Cancer: An International Consortium Report. CLINICAL ONCOLOGY. 2021; 33(5). DOI:10.1016/j.clon.2020.12.008. PMID:33358283. IF:4,925.
Martinez E, Garin O, Pardo Y, Fernandez P, Guix B, Gutierrez C, Boladeras A, Ferrer F, Hernandez T, Ayala A, Egiguren M, Fernandez G, Munoz V, Macias V, Pera J, Pont A, Ferrer M, Guedea F, Sancho G, Palou J, Multicentric Spanish Clinicall GRP. Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost: a prospective multicenter study. Journal of Contemporary Brachytherapy. 2021; 13(1). DOI:10.5114/jcb.2021.103580. PMID:34025730. IF:1,788.
Pötter R, Tanderup K, Schmid MP, Jürgenliemk-Schulz I, Haie-Meder C, Fokdal LU, Sturdza AE, Hoskin P, Mahantshetty U, Segedin B, Bruheim K, Huang F, Rai B, Cooper R, van der Steen-Banasik E, Van Limbergen E, Pieters BR, Tan LT, Nout RA, De Leeuw AAC, et al. [Majercakova K]. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncology. 2021;22(4):538-547. DOI: 1016/S1470-2045(20)30753-1. PMID: 33794207. IF:54,433.
Provencio M, Majem M, Guirado M, Massuti B, de Las Penas R, Ortega AL, Domine M, Marse R, Sala MA, Paredes A, Moran T, Vazquez S, Coves J, Larriba JLG, Sanchez JM, Vicente D, Farre N, Fornos LF, Zapata I, Franco F, Serna R, Romero A, Isla D. Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection. LUNG CANCER. 2021; 153. DOI:10.1016/j.lungcan.2021.01.005. PMID:33453470. IF:6,081.
Sanguedolce F, Pardo GS, Sanchez AM, Lucena JB, Pisano F, Cortez JC, Territo A, Perez JH, Sopena JG, Lopez CE, Breda A, Redorta JP. Radiation-induced haemorrhagic cystitis after prostate cancer radiotherapy: factors associated to hospitalization and treatment strategies. Prostate International. 2021; 9(1). DOI:10.1016/j.prnil.2020.07.006. PMID:33912514. IF:3,070.
Seppenwoolde Y, Majercakova K, Buschmann M, Dorr E, Sturdza AE, Schmid MP, Potter R, Georg D. Early morbidity and dose-volume effects in definitive radiochemotherapy for locally advanced cervical cancer: a prospective cohort study covering modern treatment techniques. STRAHLENTHERAPIE UND ONKOLOGIE. 2021; 197(6). DOI:10.1007/s00066-021-01781-6. PMID:33929558. IF:4,033.
Zhao M, Sanz J, Rodríguez N, Foro P, Reig A, Membrive I, Li X, Huang Y, Montezuma L, Martínez A, Manuel A. Weekly radiotherapy in elderly breast cancer patients: a comparison between two hypofractionation schedules. Clinical & Translational Oncology. 2021;23(2):372-377. DOI:10.1007/s12094-020-02430-7. PMID: 32617869. IF:3,340.

ASSOCIATED GROUPS

Radiation Oncology

Main lines of research

Modulation of Radiosensitivity

SBRT for Patients with Lung Cancer and with Oligometastases

Radiation Therapy Based on PET/CT Functional Imaging of Tumours

Challenges

Group coordination

Members

Publications 2023

Publications 2022

Publications 2021

Main lines of research

Modulation of Radiosensitivity

SBRT for Patients with Lung Cancer and with Oligometastases

Radiation Therapy Based on PET/CT Functional Imaging of Tumours

Challenges

Group coordination

Members

Publications 2023

Publications 2022

Publications 2021

Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau